Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] (Translational Oncology (2021) 14(9), (S1936523321001443), (10.1016/j.tranon.2021.101152))

Satoko Koga; Hideya Onishi; Shogo Masuda; Akiko Fujimura; Shu Ichimiya; Kazunori Nakayama; Akira Imaizumi; Kenichi Nishiyama; Masayuki Kojima; Kei Miyoshi; Katsuya Nakamura; Masayo Umebayashi; Takashi Morisaki; Masafumi Nakamurab

doi:10.1016/j.tranon.2022.101344

Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] (Translational Oncology (2021) 14(9), (S1936523321001443), (10.1016/j.tranon.2021.101152))

Satoko Koga, Hideya Onishi, Shogo Masuda, Akiko Fujimura, Shu Ichimiya, Kazunori Nakayama, Akira Imaizumi, Kenichi Nishiyama, Masayuki Kojima, Kei Miyoshi, Katsuya Nakamura, Masayo Umebayashi, Takashi Morisaki, Masafumi Nakamurab

Advanced Medical Intiatives

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The authors regret that they missed the below corrections. Abstract: 1P 11th line / Result: 6P second line / Result: 8P first line/ Discussion: 11P second line “autocrine”→“autologous”. The authors would like to apologise for any inconvenience caused.

Original language	English
Article number	101344
Journal	Translational Oncology
Volume	17
DOIs	https://doi.org/10.1016/j.tranon.2022.101344
Publication status	Published - Mar 2022

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.tranon.2022.101344

Fingerprint

Dive into the research topics of 'Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] (Translational Oncology (2021) 14(9), (S1936523321001443), (10.1016/j.tranon.2021.101152))'. Together they form a unique fingerprint.

Cite this

Koga, S., Onishi, H., Masuda, S., Fujimura, A., Ichimiya, S., Nakayama, K., Imaizumi, A., Nishiyama, K., Kojima, M., Miyoshi, K., Nakamura, K., Umebayashi, M., Morisaki, T., & Nakamurab, M. (2022). Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] (Translational Oncology (2021) 14(9), (S1936523321001443), (10.1016/j.tranon.2021.101152)). Translational Oncology, 17, [101344]. https://doi.org/10.1016/j.tranon.2022.101344

Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] (Translational Oncology (2021) 14(9), (S1936523321001443), (10.1016/j.tranon.2021.101152)). / Koga, Satoko; Onishi, Hideya; Masuda, Shogo et al.

In: Translational Oncology, Vol. 17, 101344, 03.2022.

Research output: Contribution to journal › Comment/debate › peer-review

Koga, S, Onishi, H, Masuda, S, Fujimura, A, Ichimiya, S, Nakayama, K, Imaizumi, A, Nishiyama, K, Kojima, M, Miyoshi, K, Nakamura, K, Umebayashi, M, Morisaki, T & Nakamurab, M 2022, 'Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] (Translational Oncology (2021) 14(9), (S1936523321001443), (10.1016/j.tranon.2021.101152))', Translational Oncology, vol. 17, 101344. https://doi.org/10.1016/j.tranon.2022.101344

Koga S, Onishi H, Masuda S, Fujimura A, Ichimiya S, Nakayama K et al. Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] (Translational Oncology (2021) 14(9), (S1936523321001443), (10.1016/j.tranon.2021.101152)). Translational Oncology. 2022 Mar;17:101344. doi: 10.1016/j.tranon.2022.101344

Koga, Satoko ; Onishi, Hideya ; Masuda, Shogo et al. / Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] (Translational Oncology (2021) 14(9), (S1936523321001443), (10.1016/j.tranon.2021.101152)). In: Translational Oncology. 2022 ; Vol. 17.

@article{7817936cd09f4e5687bbf5372e86179a,

title = "Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] (Translational Oncology (2021) 14(9), (S1936523321001443), (10.1016/j.tranon.2021.101152))",

abstract = "The authors regret that they missed the below corrections. Abstract: 1P 11th line / Result: 6P second line / Result: 8P first line/ Discussion: 11P second line “autocrine”→“autologous”. The authors would like to apologise for any inconvenience caused.",

author = "Satoko Koga and Hideya Onishi and Shogo Masuda and Akiko Fujimura and Shu Ichimiya and Kazunori Nakayama and Akira Imaizumi and Kenichi Nishiyama and Masayuki Kojima and Kei Miyoshi and Katsuya Nakamura and Masayo Umebayashi and Takashi Morisaki and Masafumi Nakamurab",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = mar,

doi = "10.1016/j.tranon.2022.101344",

language = "English",

volume = "17",

journal = "Translational Oncology",

issn = "1936-5233",

publisher = "Neoplasia Press",

}

TY - JOUR

T1 - Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] (Translational Oncology (2021) 14(9), (S1936523321001443), (10.1016/j.tranon.2021.101152))

AU - Koga, Satoko

AU - Onishi, Hideya

AU - Masuda, Shogo

AU - Fujimura, Akiko

AU - Ichimiya, Shu

AU - Nakayama, Kazunori

AU - Imaizumi, Akira

AU - Nishiyama, Kenichi

AU - Kojima, Masayuki

AU - Miyoshi, Kei

AU - Nakamura, Katsuya

AU - Umebayashi, Masayo

AU - Morisaki, Takashi

AU - Nakamurab, Masafumi

PY - 2022/3

Y1 - 2022/3

N2 - The authors regret that they missed the below corrections. Abstract: 1P 11th line / Result: 6P second line / Result: 8P first line/ Discussion: 11P second line “autocrine”→“autologous”. The authors would like to apologise for any inconvenience caused.

AB - The authors regret that they missed the below corrections. Abstract: 1P 11th line / Result: 6P second line / Result: 8P first line/ Discussion: 11P second line “autocrine”→“autologous”. The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85122800535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122800535&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2022.101344

DO - 10.1016/j.tranon.2022.101344

M3 - Comment/debate

AN - SCOPUS:85122800535

VL - 17

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

M1 - 101344

ER -